Spontaneous Subcapsular Hematoma from Rivaroxaban

Abstract
Rivaroxaban was approved for stroke prevention for non-valvular atrial fibrillation in 2011, with added advantage of decreased risk of bleeding in comparison to coumadin, made it a good alternative for coumadin.